| Name | Title | Contact Details |
|---|
Banner is a global gelatin-based drug delivery and specialty pharmaceutical company. We are committed to researching, developing and producing unique oral dosage forms for the Pharmaceutical Health Care Industry. Through our innovative technologies and
ARTMS Inc. is the global leader in the development of novel technologies and products for enabling the cyclotron production of the world’s most-used diagnostic imaging isotopes.
Vetagro is a company that specializes in feed additive development and production for the animal feed industry. They focus on developing targeted solutions through scientific research, technological development, innovative formulation, and a focus on q...
Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Elevar`s lead proprietary drug candidates include rivoceranib (apatinib) and Apealea® (paclitaxel micellar). Rivoceranib is the first small-molecule tyrosine kinase inhibitor (TKI) to be approved in gastric cancer (China, Dec 2014). It has been granted Orphan Drug designation in the U.S., Europe and South Korea and has been clinically tested in over 1,000 patients worldwide in numerous cancer indications. Apealea® (paclitaxel micellar) is a non-Cremophor EL based formulation of paclitaxel that received marketing authorization by the European Commission in November 2018, making it Europe`s first non-Cremophor EL formulation of paclitaxel approved for use in ovarian cancer. Elevar Therapeutics has offices in Utah, California and South Korea.